Webinar: Risky business: Understanding and managing residual CVD risk
Optimal detection and control of known risk factors is the cornerstone of CVD prevention.1 In recent decades, the management of modifiable risk factors, such as dyslipidaemia, hypertension and hyperglycaemia has undergone significant advancement.2
New and more aggressive pharmacotherapy regimes have driven treatment targets to levels not previously achievable and led to improvements in cardiovascular outcomes.
Yet CVD remains a leading cause of death in Australia.3
Even when guideline-based preventative measures are implemented and target levels for modifiable risk factors are achieved, a significant risk of CVD events persists.
This is known as residual CVD risk.4
Streamed live during Heart Week 2023, this webinar explores the latest evidence about managing the drivers of residual CVD risk. A panel of international and Australian experts break down novel biomarkers, predictors and treatment for residual risk, supported by a case study to illustrate application in primary care.
Duration: 1 hour
Date recorded: 3 May 2023
Topics covered:
Optimising current CVD risk assessment and management
Residual cardiovascular risk in diabetes: what do we know from the Australian experience?
Lipoprotein(a) as a residual risk factor for atherosclerotic CVD
Polygenic risk scores and their application in primary care
Expert panellists
Prof Sandosh Padmanabhan
Professor of Cardiovascular Genomics and Therapeutics at the University of Glasgow Honorary Consultant Physician at the Queen Elizabeth University Hospital, Glasgow
Professor Sandosh Padmanabhan is the Professor of Cardiovascular Genomics and Therapeutics at the University of Glasgow, and Honorary Consultant Physician at the Queen Elizabeth University Hospital, Glasgow. His main research interests are in hypertension, pharmacogenomics and precision medicine specifically related to population level risk stratification and implementation. He is the academic lead of two work streams of the Glasgow Living Laboratory for Precision Medicine - Pharmacogenomics and Digital Health Validation Lab where he is leveraging the triple helix paradigm of NHS-Academia-Industry partnerships to realise the potential of precision medicine for all across Glasgow’s socio-economic and demographic spectrum. He is a Commissioner of the Commission on Human Medicines advising UK government on safety and efficacy of medicines, a Fellow of the Royal College of Physicians, the British Pharmacological Society, the British and Irish Hypertension Society and the American Heart Association.
Assoc Prof Peter Psaltis
Co-Deputy Director of South Australian Health and Medical Research Institute (SAHMRI) Head of Interventional Cardiology at the Royal Adelaide Hospital
Associate Professor Peter Psaltis is an Academic Cardiologist who holds a L3 NHF Future Leader Fellowship and Faculty positions at the University of Adelaide, Central Adelaide Local Health Network and SAHMRI. He is co-Deputy Director of SAHMRI, co-leads its Lifelong Health Theme and leads its Heart and Vascular Program. He is also Head of Interventional Cardiology at the Royal Adelaide Hospital. Psaltis completed his PhD in 2009, before undertaking a postdoctoral fellowship as an NHMRC CJ Martin Fellow at the Mayo Clinic, USA (2009-2012) and a fellowship in Interventional Cardiology at Monash Health, Melbourne (2013-2014). His research focuses on finding new cellular, molecular and mechanical mediators of atherosclerosis that can be targeted with new treatments. Psaltis has secured >$20 million of research funding, including four CIA NHMRC Project Grants and received the 2021 NHMRC Marshall and Warren Award for Innovation. He has authored >170 manuscripts. He is Past-President of the Australian Atherosclerosis Society and serves on the CSANZ Scientific Committee.
Prof Sophia Zoungas
Head, School of Public Health and Preventive Medicine and Division of Metabolism, Ageing and Genomics, Monash University
Professor Sophia Zoungas, MBBS, FRACP, PhD, is the head of Monash University’s School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia, and also leads the School’s Metabolism, Ageing and Genomics Division. She is an endocrinologist with clinical appointments at both Alfred Health and Monash Health, Melbourne, Victoria, Australia. She leads clinical and health services research groups and collaborates extensively both locally and internationally in the specialty areas of diabetes, cardiovascular disease, kidney disease, and healthy aging. She served as President of the Australian Diabetes Society from 2016 to 2018 and Clinical Director of the National Association of Diabetes Centres from 2009 to 2019. Sophia has over 280 publications in peer-reviewed journals, including the New England Journal of Medicine, Lancet, Annals of Internal Medicine, British Medical Journal, and Nature Reviews.
Prof Jan Radford
Professor in General Practice and Director of the Launceston Clinical School at the University of Tasmania
Professor Jan Radford has practised as a general medical practitioner since 1986. She is a Professor in General Practice and Director of the Launceston Clinical School at the University of Tasmania. Jan is a medical educator who pioneered a one-week clinical placement in residential aged care facilities for final year medical students. This formed the basis of her PhD. Jan has also established and leads a general practice-based research network in the north of Tasmania. She has a research interest in clinical projects using large collated electronic health record datasets. She has led a project in the area of chronic kidney disease and collaborated with others in the area of atrial fibrillation. Other areas of interest are familial hypercholesterolaemia, interventions to improve the quality of general practice care, and interventions aimed at members of the community who shy away from preventative health care. In 2017 she obtained a Churchill Scholarship travelling to England, Scotland, and the Netherlands to investigate the research use of general practice electronic datasets.
References
- Absolute CVD risk clinical guidelines, Available here.
- Prioritizing Health – Residual Cardiovascular Risk: Beyond Traditional Risk Factors, 25 February 2022, available here.
- Heart, stroke and vascular disease: Australian facts, 09 February 2023, Available here.
- Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020 May 13;7:88. doi: 10.3389/fcvm.2020.00088. PMID: 32478100; PMCID: PMC7237700.
Last updated01 June 2023